Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

56.14 -0.60 (-1.06%)
Official Closing Price Updated: 4:10 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
94 95 Next >
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Novo Nordisk may have found a winner in amycretin. 
Via The Motley Fool
Allurion Catapults 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk
While the other companies are testing weight-loss drugs, Allurion has a different approach to obesity. 
Via Investor's Business Daily
Customers Bancorp, Twilio, Dana And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy
The results also come as a relief following a selloff triggered by disappointing results from Novo’s CagriSema trial, which many deemed overblown. 
Via Stocktwits
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
 
Via Benzinga
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Via The Motley Fool
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned. 
Via Benzinga
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 inhibitors with potential for other diseases. 
Via Benzinga
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing good growth, while it is not too expensive. 
Via Chartmill
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
Novo Nordisk Unusual Options Activity
 
Via Benzinga
Not A Turnaround But Could Be Soon Novo Nordisk
On the weekly chart, NVO fell right down to the 200-week moving average. Clearly the leadership is showing a gross lack of leadership. 
Via Talk Markets
Topics Stocks / Equities
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
5 Stocks to Buy Now for Big Returns in 2025
Here are five stocks to buy now that could offer investors upside in 2025. 
Via The Motley Fool
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss
Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and placebo over 72 weeks. 
Via Benzinga
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs. 
Via Stocktwits
Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts
The price negotiations will take place in 2025 and go into effect in 2027 for a new list of 15 drugs. 
Via Investor's Business Daily
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Via The Motley Fool
Topics Government
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
The company cut its fourth-quarter guidance by 5%. But there's still a lot happening for Lilly. 
Via Investor's Business Daily
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
A cooler-than-expected December producer inflation report failed to ignite lasting gains on Wall Street Tuesday, reflecting lingering concerns about persistently high inflation among investors. 
Via Benzinga
Topics Economy
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity
Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down. 
Via MarketBeat
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
94 95 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.